Literature DB >> 18327994

Type 2 diabetes mellitus: prevention of macrovascular complications.

Susanne H Meeuwisse-Pasterkamp1, Melanie M van der Klauw, Bruce H R Wolffenbuttel.   

Abstract

Type 2 diabetes mellitus is a disease that affects a rapidly increasing number of patients. Most patients with Type 2 diabetes will develop vascular complications. This may be microvascular disease, such as nephropathy, retinopathy or polyneuropathy, and also macrovascular disease, such as coronary heart disease, stroke or peripheral artery disease. Optimal control of elevated blood glucose levels will reduce the symptoms of hyperglycemia and help to prevent the development of complications. In addition, treatment of hypertension and lipid disturbances has been shown to reduce the incidence and severity of vascular complications significantly. The current treatment goals focus on adequate and aggressive treatment of these three risk factors. The central dogma for treatment of blood glucose, blood pressure and cholesterol levels is 'the lower the better'. Ongoing trials evaluate the effect of further lowering these treatment goals and of specific types of medication on cardiovascular events.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18327994     DOI: 10.1586/14779072.6.3.323

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  9 in total

1.  Cortical neurons develop insulin resistance and blunted Akt signaling: a potential mechanism contributing to enhanced ischemic injury in diabetes.

Authors:  Bhumsoo Kim; Kelli A Sullivan; Carey Backus; Eva L Feldman
Journal:  Antioxid Redox Signal       Date:  2011-03-08       Impact factor: 8.401

Review 2.  New concepts in diabetic embryopathy.

Authors:  Zhiyong Zhao; E Albert Reece
Journal:  Clin Lab Med       Date:  2013-04-19       Impact factor: 1.935

3.  Hyperglycemic oxoaldehyde, glyoxal, causes barrier dysfunction, cytoskeletal alterations, and inhibition of angiogenesis in vascular endothelial cells: aminoguanidine protection.

Authors:  Sean M Sliman; Timothy D Eubank; Sainath R Kotha; M Lakshmi Kuppusamy; Shariq I Sherwani; Elizabeth Susan O'Connor Butler; Periannan Kuppusamy; Sashwati Roy; Clay B Marsh; David M Stern; Narasimham L Parinandi
Journal:  Mol Cell Biochem       Date:  2009-07-08       Impact factor: 3.396

4.  Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions.

Authors:  Dieter Schoepf; Hardeep Uppal; Rahul Potluri; Reinhard Heun
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-08-13       Impact factor: 5.270

5.  The association between urinary phytoestrogen excretion and components of the metabolic syndrome in NHANES.

Authors:  Tristan Struja; Aline Richard; Jakob Linseisen; Monika Eichholzer; Sabine Rohrmann
Journal:  Eur J Nutr       Date:  2013-12-31       Impact factor: 5.614

6.  Chronic diseases in male veterans with multiple sclerosis.

Authors:  Sherri L Lavela; Thomas R Prohaska; Sylvia Furner; Frances M Weaver
Journal:  Prev Chronic Dis       Date:  2012-02-09       Impact factor: 2.830

7.  Building a semantically annotated corpus for chronic disease complications using two document types.

Authors:  Noha Alnazzawi
Journal:  PLoS One       Date:  2021-03-18       Impact factor: 3.240

8.  Dose comparison of ultrasonic transdermal insulin delivery to subcutaneous insulin injection.

Authors:  Eun-Joo Park; Jeff Dodds; Nadine Barrie Smith
Journal:  Int J Nanomedicine       Date:  2008

9.  Genetic Risk for Psychiatric Disorders and Telomere Length.

Authors:  Alish B Palmos; Gerome Breen; Laura Goodwin; Souci Frissa; Stephani L Hatch; Matthew Hotopf; Sandrine Thuret; Cathryn M Lewis; Timothy R Powell
Journal:  Front Genet       Date:  2018-10-16       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.